Dr. Katelyn Halpape, BSP, PharmD, ACPR
Clinical Pharmacy Specialist – Neurosciences, Vancouver General Hospital
This presentation will review the key studies and headlines from 2016 and how we can apply this information to practice.
HOPE-3 (Cholesterol & BP Lowering)
EMPA-REG (Type 2 Diabetes)
LEADER (Type 2 Diabetes)
ATTACH-II (Intracranial Hemorrhage)
Arden Barry, BSc, BSc(Pharm), PharmD, ACPR Clinical Pharmacy and Research Specialist, Lower Mainland Pharmacy Services; Assistant Professor (Partner), Faculty of Pharmaceutical Sciences, University of British Columbia; Associate Member, Department of Family Practice, Faculty of Medicine, University of British Columbia
The treatment of dyslipidemia is controversial despite a plethora of available published evidence. This has led to the development of multiple dyslipidemia guidelines— while these documents differ with respect philosophy and complexity, they are more similar than they are different. This presentation aims to explore three recently published dyslipidemia guidelines with the goal of deriving a few pragmatic considerations that participants can apply in practice.
Amy Nunley, BScPh, ACPR
Review of medications used to manage NSTEACS.
Describe at least 4 risk factors for NSTE-ACS
List at least 3 medications that have mortality benefit after NSTE-ACS
List target doses and monitoring parameters for each of:
- Antiplatelets (Acetylsalicylic Acid [ASA], clopidogrel, ticagrelor)
Dr. Arden Barry, BSc, BScPharm, PharmD, ACPR
Clinical Pharmacy and Research Specialist, Lower Mainland Pharmacy Services
Assistant Professor (Partner), Faculty of Pharmaceutical Sciences, University of British Columbia
Identify recently published guidelines for the treatment of dyslipidemia
Review key clinical trials in the management of dyslipidemia published since 2012
Review the key recommendaEons relevant to pharmacists from the (to be published) updated Canadian Cardiovascular Society guidelines for the management of dyslipidemia.